JAGUAR HEALTH, INC. Share-based Payment Arrangement, Expense
JAGUAR HEALTH, INC. (JAGX) reported Share-based Payment Arrangement, Expense of $171.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-19
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $171.00K, a 38.71% decline year-over-year.
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $155.00K, a 48.50% decline year-over-year.
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $116.00K, a 68.39% decline year-over-year.
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $135.00K, a 56.45% decline year-over-year.
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for fiscal 2025 was $831.00K, a 49.36% decline from fiscal 2024.
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for fiscal 2024 was $1.64M, a 22.30% decline from fiscal 2023.
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for fiscal 2023 was $2.11M, a 36.35% decline from fiscal 2022.
- JAGUAR HEALTH, INC. share-based payment arrangement, expense for fiscal 2022 was $3.32M, a 16.51% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $171.00K 10-Q · filed 2026-08-19 | $326.00K 10-Q · filed 2026-08-19 | $442.00K derived: sum of 3 quarters · filed 2026-08-19 | $577.00K derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2026-03-31 | $155.00K 10-Q · filed 2026-05-20 | $271.00K derived: sum of 2 quarters · filed 2026-05-20 | $406.00K derived: sum of 3 quarters · filed 2026-05-20 | $685.00K derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-12-31 | $116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $251.00K derived: sum of 2 quarters · filed 2026-04-07 | $530.00K derived: sum of 3 quarters · filed 2026-08-19 | $831.00K 10-K · filed 2026-04-07 | ||||
| 2025-09-30 | $135.00K 10-Q · filed 2025-11-14 | $414.00K derived: sum of 2 quarters · filed 2026-08-19 | $715.00K 10-Q · filed 2025-11-14 | $1.08M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-06-30 | $279.00K 10-Q · filed 2026-08-19 | $580.00K 10-Q · filed 2026-08-19 | $947.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.26M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-03-31 | $301.00K 10-Q · filed 2026-05-20 | $668.00K derived: sum of 2 quarters · filed 2026-05-20 | $978.00K derived: sum of 3 quarters · filed 2026-05-20 | $1.36M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-12-31 | $367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $677.00K derived: sum of 2 quarters · filed 2026-04-07 | $1.06M derived: sum of 3 quarters · filed 2026-04-07 | $1.64M 10-K · filed 2026-04-07 | ||||
| 2024-09-30 | $310.00K 10-Q · filed 2025-11-14 | $693.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.27M 10-Q · filed 2025-11-14 | $1.85M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $383.00K 10-Q · filed 2025-08-14 | $964.00K 10-Q · filed 2025-08-14 | $1.54M derived: sum of 3 quarters · filed 2025-08-14 | $2.08M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $581.00K 10-Q · filed 2025-05-15 | $1.16M derived: sum of 2 quarters · filed 2025-05-15 | $1.70M derived: sum of 3 quarters · filed 2025-05-15 | $2.21M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $577.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.11M derived: sum of 2 quarters · filed 2025-03-31 | $1.63M derived: sum of 3 quarters · filed 2025-03-31 | $2.11M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $537.00K 10-Q · filed 2024-11-13 | $1.05M derived: sum of 2 quarters · filed 2024-11-13 | $1.53M 10-Q · filed 2024-11-13 | $1.93M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $518.00K 10-Q · filed 2024-08-13 | $998.00K 10-Q · filed 2024-08-13 | $1.40M derived: sum of 3 quarters · filed 2024-08-13 | $2.24M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $480.00K 10-Q · filed 2024-05-14 | $877.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.72M derived: sum of 3 quarters · filed 2024-05-14 | $2.56M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $397.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.24M derived: sum of 2 quarters · filed 2024-04-01 | $2.08M derived: sum of 3 quarters · filed 2024-04-01 | $3.32M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $841.00K 10-Q · filed 2022-11-14 | $1.68M derived: sum of 2 quarters · filed 2023-11-14 | $2.92M 10-Q · filed 2023-11-14 | $3.89M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $841.00K 10-Q · filed 2023-11-14 | $1.02M 10-Q · filed 2022-08-22 | $2.08M 10-Q · filed 2023-08-14 | $3.05M derived: sum of 3 quarters · filed 2023-11-14 | $4.21M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-15 | $2.21M derived: sum of 2 quarters · filed 2023-05-15 | $3.37M derived: sum of 3 quarters · filed 2023-05-15 | $4.40M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $2.31M derived: sum of 2 quarters · filed 2023-03-24 | $3.34M derived: sum of 3 quarters · filed 2023-03-24 | $3.97M 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | $1.17M 10-Q · filed 2022-11-14 | $2.20M derived: sum of 2 quarters · filed 2022-11-14 | $2.83M 10-Q · filed 2022-11-14 | $3.47M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $1.03M 10-Q · filed 2022-08-22 | $1.67M 10-Q · filed 2022-08-22 | $2.31M derived: sum of 3 quarters · filed 2022-08-22 | $2.98M derived: sum of 4 quarters · filed 2022-08-22 | ||||
| 2021-03-31 | $634.00K 10-Q · filed 2022-05-10 | $1.27M derived: sum of 2 quarters · filed 2022-05-10 | $1.95M derived: sum of 3 quarters · filed 2022-05-10 | $2.70M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $1.31M derived: sum of 2 quarters · filed 2022-03-11 | $2.06M derived: sum of 3 quarters · filed 2022-03-11 | $2.82M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $675.00K 10-Q · filed 2021-11-17 | $1.42M derived: sum of 2 quarters · filed 2021-11-17 | $2.18M 10-Q · filed 2021-11-17 | $3.19M derived: sum of 4 quarters · filed 2021-11-17 | ||||
| 2020-06-30 | $749.00K 10-Q · filed 2021-08-13 | $1.51M 10-Q · filed 2021-08-13 | $2.52M derived: sum of 3 quarters · filed 2021-08-13 | $3.63M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $760.00K 10-Q · filed 2021-05-17 | $1.77M derived: sum of 2 quarters · filed 2021-05-17 | $2.88M derived: sum of 3 quarters · filed 2021-05-17 | $3.32M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $2.12M derived: sum of 2 quarters · filed 2021-03-31 | $2.56M derived: sum of 3 quarters · filed 2021-03-31 | $2.99M 10-K · filed 2021-03-31 | $2.99M 10-K · filed 2020-04-03 | |||
| 2019-09-30 | $1.11M 10-Q · filed 2020-11-16 | $1.11M 10-Q · filed 2019-11-14 | $1.56M derived: sum of 2 quarters · filed 2020-11-16 | $1.98M 10-Q · filed 2020-11-16 | $1.98M 10-Q · filed 2019-11-14 | $2.59M derived: sum of 4 quarters · filed 2020-11-16 | ||
| 2019-06-30 | $446.00K 10-Q · filed 2020-08-13 | $446.37K 10-Q · filed 2019-08-14 | $873.00K 10-Q · filed 2020-08-13 | $872.88K 10-Q · filed 2019-08-14 | $1.48M derived: sum of 3 quarters · filed 2020-08-13 | $2.16M derived: sum of 4 quarters · filed 2020-08-13 | ||
| 2019-03-31 | $427.00K 10-Q · filed 2020-05-15 | $426.51K 10-Q · filed 2019-05-21 | $1.03M derived: sum of 2 quarters · filed 2020-05-15 | $1.71M derived: sum of 3 quarters · filed 2020-05-15 | $2.18M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $607.08K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | $1.29M derived: sum of 2 quarters · filed 2020-04-03 | $1.75M derived: sum of 3 quarters · filed 2020-04-03 | $2.02M 10-K · filed 2020-04-03 | ||||
| 2018-09-30 | $680.09K 10-Q · filed 2019-11-14 | $1.14M derived: sum of 2 quarters · filed 2019-11-14 | $1.42M 10-Q · filed 2019-11-14 | $1.60M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $464.45K 10-Q · filed 2019-08-14 | $736.70K 10-Q · filed 2019-08-14 | $920.39K derived: sum of 3 quarters · filed 2019-08-14 | $1.11M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | $272.24K 10-Q · filed 2019-05-21 | $455.93K derived: sum of 2 quarters · filed 2019-05-21 | $642.69K derived: sum of 3 quarters · filed 2019-05-21 | $858.82K derived: sum of 4 quarters · filed 2019-05-21 | ||||
| 2017-12-31 | $183.69K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | $370.44K derived: sum of 2 quarters · filed 2019-04-10 | $586.58K derived: sum of 3 quarters · filed 2019-04-10 | $814.61K 10-K · filed 2019-04-10 | ||||
| 2017-09-30 | $186.75K 10-Q · filed 2018-11-19 | $402.89K derived: sum of 2 quarters · filed 2018-11-19 | $630.92K 10-Q · filed 2018-11-19 | $870.41K derived: sum of 4 quarters · filed 2018-11-19 | ||||
| 2017-06-30 | $216.13K 10-Q · filed 2018-08-13 | $444.17K 10-Q · filed 2018-08-13 | $683.65K derived: sum of 3 quarters · filed 2018-08-13 | $933.03K derived: sum of 4 quarters · filed 2018-08-13 | ||||
| 2017-03-31 | $228.04K 10-Q · filed 2018-05-15 | $467.52K derived: sum of 2 quarters · filed 2018-05-15 | $716.90K derived: sum of 3 quarters · filed 2018-05-15 | $842.42K derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $239.49K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | $488.86K derived: sum of 2 quarters · filed 2018-04-09 | $614.38K derived: sum of 3 quarters · filed 2018-04-09 | $717.93K 10-K · filed 2018-04-09 | ||||
| 2016-09-30 | $249.38K 10-Q · filed 2017-11-20 | $374.90K derived: sum of 2 quarters · filed 2017-11-20 | $478.44K 10-Q · filed 2017-11-20 | $642.56K derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2016-06-30 | $125.52K 10-Q · filed 2017-08-09 | $229.06K 10-Q · filed 2017-08-09 | $393.18K derived: sum of 3 quarters · filed 2017-08-09 | $593.38K derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | $103.54K 10-Q/A · filed 2017-06-23 | $267.66K derived: sum of 2 quarters · filed 2017-06-23 | $467.86K derived: sum of 3 quarters · filed 2017-06-23 | $1.04M derived: sum of 4 quarters · filed 2017-06-23 | ||||
| 2015-12-31 | $164.12K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $364.32K derived: sum of 2 quarters · filed 2017-02-15 | $939.55K derived: sum of 3 quarters · filed 2017-02-15 | $992.16K 10-K · filed 2017-02-15 | ||||
| 2015-09-30 | $200.20K 10-Q · filed 2016-11-14 | $775.43K derived: sum of 2 quarters · filed 2016-11-14 | $828.05K 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | $575.23K 10-Q · filed 2016-08-15 | $627.85K 10-Q · filed 2016-08-15 | ||||||
| 2015-03-31 | $52.62K 10-Q · filed 2016-05-10 | |||||||
| 2014-12-31 | $164.16K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |